Experts Advise Against Widely Used Autism Intervention After Years

After years of widespread adoption, a treatment approach for autism is now being discouraged by experts. Recent evaluations have led specialists to reconsider its effectiveness, urging caution and highlighting potential risks associated with its continued use.

A Landmark Shift in Autism Care

After years of simmering debate, the Haute autorité de santé (HAS) has taken a decisive step: it officially removes psychoanalysis from its list of recommended interventions for children and adolescents with autism. Released on Thursday, February 12, 2026, the updated guidelines cite an “insufficient level of evidence” as the basis for this exclusion—placing psychoanalysis among methods now deemed “not recommended” by the French health authority. This marks the first substantial update to national recommendations in over a decade.

The Science Behind New Guidelines

Gone is the era of equivocal language and tentative endorsements. While previous HAS documents described psychoanalysis as a “non-consensual approach,” the latest guidance leaves little room for ambiguity. The focus shifts squarely to interventions grounded in robust scientific data. According to the HAS, only therapies with proven efficacy—namely, behavioral and developmental interventions—should be offered from the first signs of an autistic spectrum disorder, sometimes even before an official diagnosis is confirmed.

Several factors explain this decision:

• Repeated studies have failed to demonstrate convincing results for psychoanalysis.
• The urgent need for early intervention calls for methods that are measurable and replicable.
• The evolving international standards in autism care prioritize evidence-based practices.

Psychoanalysis: A Divisive Legacy

Predictably, this announcement has reignited longstanding tensions within France’s mental health community. Critics of psychoanalysis—especially many patient advocacy groups and families—have long questioned its influence on both clinical training and actual care delivery. They argue that its continued prominence ignores a lack of clear benefit, particularly given the unique challenges posed by autistic spectrum disorders. Meanwhile, numerous associations representing psychologists and psychiatrists push back against what they perceive as a narrowing of therapeutic options, stressing that not all psychotherapies lend themselves easily to standard scientific evaluation.

Between Pluralism and Evidence

Debate remains far from settled. Last autumn, HAS president Lionel Collet proposed making certain guidelines legally binding—a suggestion that met swift resistance from several professional organizations intent on preserving therapeutic pluralism. As France moves toward greater reliance on solid scientific evidence in autism care, these fractures between tradition and modernity continue to shape the landscape, raising complex questions about how best to support those affected by autism and their families.